

Robert G Maki

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7110627/robert-g-maki-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

429
papers

35,978
citations

93
h-index

186
g-index

477
ext. papers

41,358
ext. citations

6.1
avg, IF

6.72
L-index

#	Paper	IF	Citations
429	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2	3577
428	A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. <i>Nature Medicine</i> , 2000 , 6, 991-7	50.5	1675
427	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 373, 1097-104	40	1022
426	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 295-302	40	908
425	NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8 Suppl 2, S1-41; quiz S42-43	7.3	828
424	Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. <i>Journal of Clinical Oncology</i> , 2008 , 26, 626-32	2.2	801
423	A framework for advancing our understanding of cancer-associated fibroblasts. <i>Nature Reviews Cancer</i> , 2020 , 20, 174-186	31.3	790
422	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. <i>Lancet Oncology, The</i> , 2011 , 12, 1004-12	21.7	732
421	Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. <i>Clinical Cancer Research</i> , 2005 , 11, 4182-90	12.9	668
420	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. <i>New England Journal of Medicine</i> , 2010 , 363, 1727-33	59.2	622
419	Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2824-31	2.2	594
418	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5352-9	2.3	583
417	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1493-1501	21.7	544
416	Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2755-63	2.2	541
415	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. <i>Nature Genetics</i> , 2010 , 42, 715-21	36.3	521
414	Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005 , 16, 566-78	10.3	518
413	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 786-93	2.2	466

412	Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3133-40	2.2	461
411	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017 , 171, 950-965.e28	56.2	451
410	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1629-37	4.0	445
409	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). <i>Cancer</i> , 2008 , 112, 608-15	6.4	375
408	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 942-6	8.9	354
407	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. <i>Lancet Oncology, The</i> , 2009 , 10, 1045-52	21.7	352
406	A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 644-53	5	341
405	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 835-40	2.2	297
404	Advances in sarcoma genomics and new therapeutic targets. <i>Nature Reviews Cancer</i> , 2011 , 11, 541-57	31.3	291
403	A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2005 , 11, 241-7	2.2	290
402	Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 853-9	5	284
401	Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3154-60	2.2	258
400	R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4541-7	2.2	257
399	Altered bone and mineral metabolism in patients receiving imatinib mesylate. <i>New England Journal of Medicine</i> , 2006 , 354, 2006-13	59.2	248
398	Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1480-90	2.2	247
397	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. <i>Nature Medicine</i> , 2007 , 13, 748-53	50.5	243
396	Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 25-33	5	235
395	Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. <i>Annals of Surgery</i> , 2007 , 245, 347-52	7.8	235

394	High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 207-18	5	229
393	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. <i>Nature</i> , 2010 , 467, 849-53	50.4	229
392	Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. <i>International Journal of Cancer</i> , 2002 , 100, 623-6	7.5	225
391	Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7135-42	2.2	218
390	Molecular characterization of pediatric gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 3204-15	12.9	211
389	KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. <i>Cancer Research</i> , 2009 , 69, 7175-9	10.1	208
388	Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2005 , 27, 179-87	1.2	207
387	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1563-70	2.7	192
386	Activity of Sorafenib against desmoid tumor/deep fibromatosis. <i>Clinical Cancer Research</i> , 2011 , 17, 4082-90	12.9	191
385	Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. <i>Clinical Cancer Research</i> , 2007 , 13, 2643-50	12.9	189
384	NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5 Suppl 2, S1-29; quiz S30	7.3	187
383	Malignant peripheral nerve sheath tumors. <i>Oncologist</i> , 2014 , 19, 193-201	5.7	186
382	Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. <i>Cancer Research</i> , 2007 , 67, 6626-36	10.1	186
381	Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. <i>American Journal of Pathology</i> , 2003 , 163, 691-700	5.8	185
380	Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3148-53	2.2	184
379	NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST) Update of the NCCN Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, S-1-S-29	7.3	183
378	Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. <i>Clinical Cancer Research</i> , 2004 , 10, 3282-90	12.9	175
377	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012 , 118, 1649-55	6.4	171

376	Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. <i>Clinical Cancer Research</i> , 2010 , 16, 4884-91	12.9	171
375	Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4985-95	2.2	171
374	Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8862-7	11.5	168
373	Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. <i>Annals of Surgery</i> , 2007 , 246, 105-13	7.8	159
372	Sorafenib for Advanced and Refractory Desmoid Tumors. <i>New England Journal of Medicine</i> , 2018 , 379, 2417-2428	59.2	155
371	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2013 , 14, 371-82	21.7	152
370	Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. <i>Modern Pathology</i> , 2017 , 30, 1433-1442	9.8	152
369	Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5484-92	2.2	152
368	Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. <i>Annals of Oncology</i> , 2004 , 15, 1667-72	10.3	150
367	Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. <i>Journal of Clinical Investigation</i> , 2007 , 117, 3248-57	15.9	150
366	A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 282-4	9.7	145
365	Advanced chondrosarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2013 , 24, 2916-22	10.3	142
364	Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. <i>International Journal of Cancer</i> , 1996 , 69, 340-9	7.5	141
363	Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. <i>Annals of Oncology</i> , 2017 , 28, 2595-2605	10.3	139
362	Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. <i>Clinical Cancer Research</i> , 2007 , 13, 4874-81	12.9	134
361	A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration trial. <i>Cancer</i> , 2014 , 123, 2112-21	6.4	133
360	A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. <i>Clinical Cancer Research</i> , 2008 , 14, 8191-7	12.9	131
359	Evidence-based recommendations for local therapy for soft tissue sarcomas. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1003-8	2.2	131

358	Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). <i>Cancer</i> , 2010 , 116, 2258-65	6.4	128
357	Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4567-74	2.2	128
356	Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. <i>Annals of Surgery</i> , 2013 , 258, 422-9	7.8	125
355	Opportunities for improving the therapeutic ratio for patients with sarcoma. <i>Lancet Oncology, The</i> , 2007 , 8, 513-24	21.7	123
354	Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). <i>Cancer</i> , 2013 , 119, 1555-61	6.4	122
353	Human homologue of murine tumor rejection antigen gp96: 5' regulatory and coding regions and relationship to stress-induced proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 5658-62	11.5	121
352	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. <i>Lancet Oncology, The</i> , 2016 , 17, 1261-71	21.7	121
351	Stress-induced proteins in immune response to cancer. <i>Current Topics in Microbiology and Immunology</i> , 1991 , 167, 109-23	3.3	120
350	The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. <i>Annals of Surgery</i> , 2004 , 240, 686-95; discussion 695-7	7.8	119
349	Patient-derived xenografts for individualized care in advanced sarcoma. <i>Cancer</i> , 2014 , 120, 2006-15	6.4	118
348	Extraskeletal myxoid chondrosarcoma: a retrospective review from 2 referral centers emphasizing long-term outcomes with surgery and chemotherapy. <i>Cancer</i> , 2008 , 113, 3364-71	6.4	115
347	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. <i>Sarcoma</i> , 2013 , 2013, 168145	3.1	114
346	Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. <i>Clinical Cancer Research</i> , 2009 , 15, 5902-9	12.9	114
345	Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. <i>Journal of the American College of Surgeons</i> , 2012 , 215, 53-9; discussion 59-60	4.4	108
344	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020 , 127, 96-107	7.5	108
343	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3898-3905	2.2	107
342	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2012 , 48, 3036-44	7.5	105
341	Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1875-84	2.2	102

340	Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 170-81	12.9	101
339	Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii35-8	10.3	98
338	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012 , 118, 3330-6	6.4	97
337	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1424-1431	2.2	93
336	New inhibitors of renin that contain novel phosphostatine Leu-Val replacements. <i>Journal of Medicinal Chemistry</i> , 1990 , 33, 534-42	8.3	93
335	Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. <i>Clinical Cancer Research</i> , 2004 , 10, 1250-4	12.9	91
334	Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2007 , 14, 134-42	3.1	90
333	Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii89-93	10.3	88
332	Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. <i>Cancer</i> , 2003 , 98, 832-40	6.4	87
331	Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2012 , 23, 1601-7	10.3	84
330	The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 569-78	5	83
329	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1020-1044	2.2	83
328	Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. <i>Cancer</i> , 2012 , 118, 5878-87	6.4	82
327	Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3509-3509	2.2	82
326	Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. <i>Annals of Oncology</i> , 2013 , 24, 252-7	10.3	80
325	Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. <i>Oncologist</i> , 2007 , 12, 999-1006	9.6	80
324	Role of interleukin 12 and costimulators in T cell anergy in vivo. <i>Journal of Experimental Medicine</i> , 1997 , 186, 1119-28	16.6	78
323	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3433-3439	2.2	77

322	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. <i>European Journal of Cancer</i> , 2011 , 47, 1006-12	7.5	77
321	Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. <i>Clinical Cancer Research</i> , 2009 , 15, 6862-70	12.9	77
320	Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2501-2501	2.2	77
319	The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. <i>Clinical Cancer Research</i> , 2012 , 18, 2638-47	12.9	76
318	Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3-3	2.2	76
317	A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 1964-72	4	75
316	Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2010 , 5, 2044-6	8.9	69
315	Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. <i>European Journal of Cancer</i> , 2015 , 51, 210-7	7.5	67
314	IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. <i>Journal of Pathology</i> , 2010 , 221, 300-7	9.4	67
313	A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. <i>Cancer</i> , 2005 , 103, 1431-4	8.4	66
312	Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2005 , 23, 9011-9011	2.2	66
311	Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67 Suppl 1, S25-43	3.5	65
310	A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. <i>Investigational New Drugs</i> , 2012 , 30, 1193-202	4.3	63
309	Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum. <i>Neurosurgery</i> , 2013 , 73, 673-80; discussion 680	3.2	62
308	Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. <i>European Journal of Cancer</i> , 2015 , 51, 2413-22	7.5	59
307	Development and clinical application of an integrative genomic approach to personalized cancer therapy. <i>Genome Medicine</i> , 2016 , 8, 62	14.4	58
306	A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. <i>American Journal of Pathology</i> , 2008 , 172, 1069-80	5.8	58
305	Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. <i>Annals of Surgical Oncology</i> , 2011 , 18, 328-36	3.1	57

304	A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 6704-11	12.9	57
303	First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. <i>European Journal of Cancer</i> , 2012 , 48, 547-63	7.5	55
302	Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 309-19	3.5	55
301	Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e184060	13.4	54
300	Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1551-9	3.1	53
299	Why do patients with low-grade soft tissue sarcoma die?. <i>Annals of Surgical Oncology</i> , 2008 , 15, 3550-60	3.1	50
298	Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9502-9502	2.2	50
297	Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. <i>JAMA Oncology</i> , 2017 , 3, 944-952	13.4	49
296	Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. <i>British Journal of Cancer</i> , 2013 , 109, 1717-24	8.7	49
295	Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10502-10502	2.2	49
294	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. <i>Oncolmmunology</i> , 2020 , 9, 1747340	7.2	49
293	Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. <i>European Journal of Cancer</i> , 2015 , 51, 1611-7	7.5	48
292	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1081	2.2	48
291	Chemotherapy in clear cell sarcoma. <i>Medical Oncology</i> , 2011 , 28, 859-63	3.7	47
290	Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. <i>Archives of Pathology and Laboratory Medicine</i> , 2010 , 134, 165-70	5	47
289	Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis. <i>Cancer</i> , 2007 , 110, 2050-60	6.4	46
288	Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. <i>Journal of Clinical Oncology</i> , 2018 , 36, 210-216	2.2	46
287	Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10006-10006	2.2	45

286	A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. <i>Oncologist</i> , 2002 , 7, 531-8	5.7	44
285	Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. <i>Sarcoma</i> , 2015 , 2015, 532478	3.1	43
284	New therapeutic targets in soft tissue sarcoma. <i>Advances in Anatomic Pathology</i> , 2012 , 19, 170-80	5.1	43
283	Sarcomas. <i>Pediatric Clinics of North America</i> , 2015 , 62, 179-200	3.6	42
282	Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 10009-10009	2.2	42
281	Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review. <i>JAMA Oncology</i> , 2019 , 5, 254-260	13.4	42
280	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018 , 23, 62-70	5.7	42
279	Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3377-83	3.1	41
278	Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. <i>Oncologist</i> , 2015 , 20, 433-9	5.7	41
277	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. <i>Annals of Oncology</i> , 2012 , 23, 1335-1340	10.3	41
276	NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004 , 2 Suppl 1, S-1-26; quiz 27-30	7.3	40
275	Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. <i>Targeted Oncology</i> , 2013 , 8, 211-213	5	39
274	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020 , 31, 1506-1517	10.3	39
273	Evaluation of the rate constant for the reaction OH+H2CO: Application of modeling and sensitivity analysis techniques for determination of the product branching ratio. <i>Journal of Chemical Physics</i> , 1989 , 91, 4088-4097	3.9	37
272	GI Stromal Tumors: 15 Years of Lessons From a Rare Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1849-54		36
271	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , 2017 , 146, 531-537	4.9	35
270	Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement. <i>Journal of Medicinal Chemistry</i> , 1987 , 30, 2137-44	8.3	35
269	SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2004 , 22, 3001-3001	2.2	35

268	Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2019 , 20, 877-886	21.7	34
267	Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. <i>Annals of Oncology</i> , 2013 , 24, 1924-1930	10.3	34
266	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. <i>Modern Pathology</i> , 2019 , 32, 1772-1785	9.8	33
265	Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 1955-68	8.3	33
264	De novo osteogenic sarcoma in patients older than forty: benefit of multimodality therapy. <i>Clinical Orthopaedics and Related Research</i> , 2005 , 438, 110-5	2.2	33
263	Cascades of transcriptional induction during human lymphocyte activation. <i>European Journal of Cell Biology</i> , 2001 , 80, 321-8	6.1	33
262	Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Oncology</i> , 2018 , 29, 857-871	10.3	32
261	Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11006-11006	2.2	32
260	Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. <i>Annals of Oncology</i> , 2013 , 24, 537-542	10.3	31
259	Lyman-alpha. photometry: curve of growth determination, comparison to theoretical oscillator strength, and line absorption calculations at high temperature. <i>The Journal of Physical Chemistry</i> , 1985 , 89, 4815-4821		31
258	Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11015-11015	2.2	31
257	International expert opinion on patient-tailored management of soft tissue sarcomas. <i>European Journal of Cancer</i> , 2014 , 50, 679-89	7.5	30
256	EBV-Associated Smooth Muscle Neoplasms: Solid Tumors Arising in the Presence of Immunosuppression and Autoimmune Diseases. <i>Sarcoma</i> , 2008 , 2008, 859407	3.1	30
255	Management of Soft Tissue Sarcoma 2013 ,		29
254	Pediatric sarcomas occurring in adults. <i>Journal of Surgical Oncology</i> , 2008 , 97, 360-8	2.8	29
253	The enantio- and diastereoselective synthesis of the first phospho-statine derivative. <i>Tetrahedron Letters</i> , 1986 , 27, 2337-2340	2	29
252	The intricate interplay among body weight, stress, and the immune response to friend or foe. <i>Journal of Clinical Investigation</i> , 2003 , 111, 183-185	15.9	29
251	Angiosarcomas and other sarcomas of endothelial origin. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 975-88	3.1	27

250	A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. <i>Sarcoma</i> , 2006 , 2006, 15947	3.1	27
249	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11008-11008	2.2	27
248	Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 528-34	2.7	26
247	Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. <i>Journal of Clinical Oncology</i> , 2018 , 36, 194-201	2.2	26
246	Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). <i>Leukemia Research</i> , 2010 , 34, 827-9	2.7	25
245	Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. <i>Rare Tumors</i> , 2015 , 7, 5992	1.1	24
244	Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy. <i>Frontiers in Oncology</i> , 2015 , 5, 186	5.3	24
243	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Cancer</i> , 2019 , 125, 2610-2620	6.4	23
242	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015 , 20, 823-30	5.7	23
241	The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. <i>Clinical Cancer Research</i> , 2006 , 12, 6203-4	12.9	23
240	Mapping of the genes for human endoplasmic reticular heat shock protein gp96/grp94. <i>Somatic Cell and Molecular Genetics</i> , 1993 , 19, 73-81		23
239	Potent, low molecular weight renin inhibitors containing a C-terminal heterocycle: hydrogen bonding at the active site. <i>Journal of Medicinal Chemistry</i> , 1990 , 33, 1582-90	8.3	23
238	Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2596-2596	2.2	23
237	TERT promoter mutations in solitary fibrous tumour. <i>Histopathology</i> , 2018 , 73, 843-851	7.3	22
236	Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Annals of Oncology</i> , 2018 , 29, 1995-2002	10.3	22
235	Soft tissue sarcoma as a model disease to examine cancer immunotherapy. <i>Current Opinion in Oncology</i> , 2001 , 13, 270-4	4.2	22
234	A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11005-11005	2.2	22
233	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , 2015 , 51, 852-60	7.5	21

232	Sarcomas with spindle cell morphology. <i>Seminars in Oncology</i> , 2009 , 36, 324-37	5.5	20
231	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10503-10503	2.2	20
230	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11001-11001	2.2	20
229	Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. <i>Current Problems in Surgery</i> , 2003 , 40, 144-93	2.8	20
228	An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. <i>Nature Cell Biology</i> , 2019 , 21, 203-213	23.4	19
227	Mechanisms of sarcomagenesis. <i>Hematology/Oncology Clinics of North America</i> , 2005 , 19, 427-49, v	3.1	19
226	Benign mesenchymal stromal cells in human sarcomas. <i>Clinical Cancer Research</i> , 2010 , 16, 5630-40	12.9	18
225	Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. <i>Annals of Oncology</i> , 2012 , 23, 2205-2206	10.3	18
224	A context dependent role for Wnt signaling in tumorigenesis and stem cells. <i>Cell Cycle</i> , 2008 , 7, 720-4	4.7	18
223	Role of chemotherapy in patients with soft tissue sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 229-36	3.5	18
222	Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy. <i>Current Treatment Options in Gastroenterology</i> , 2004 , 7, 13-17	2.5	18
221	A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13600-e13600	2.2	18
220	Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review. <i>JAMA Oncology</i> , 2016 , 2, 941-7	13.4	18
219	Future directions for immunotherapeutic intervention against sarcomas. <i>Current Opinion in Oncology</i> , 2006 , 18, 363-8	4.2	17
218	A SARC global collaborative phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. <i>Journal of Clinical Oncology</i> , 2009 , 27, 10503-10503	2.2	17
217	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019 , 9, 14551	4.9	16
216	Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. <i>Leukemia Research</i> , 2013 , 37, 790-4	2.7	16
215	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA10502-LBA10502	2.2	16

214	First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), □ cemiplimab in patients (pts) with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2508-2508	2.2	16
213	DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). <i>Journal of Clinical Oncology</i> , 2006 , 24, 9522-9522	2.2	15
212	CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. <i>Genes Chromosomes and Cancer</i> , 2012 , 51, 186-95	5	14
211	Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). <i>Journal of Clinical Oncology</i> , 2007 , 25, 10001-10001	2.2	14
210	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104	6.4	14
209	Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS). <i>Annals of Oncology</i> , 2019 , 30, v683	10.3	13
208	Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10514-10514	2.2	13
207	A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11016-11016	2.2	13
206	Treatment of soft tissue sarcoma: a focus on earlier stages. <i>Future Oncology</i> , 2017 , 13, 13-21	3.6	12
205	Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2019 , 120, 132-139	7.5	12
204	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019 , 120, 1026-1032	8.7	12
203	Other targetable sarcomas. <i>Seminars in Oncology</i> , 2009 , 36, 358-71	5.5	12
202	Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10531-10531	2.2	12
201	Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10533-10533	2.2	12
200	A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10004-10004	2.2	12
199	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints: A Study Based on a Multicenter-Pooled Database of 31 International Sarcoma Centers. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019 , 101, 1309-1318	5.6	12
198	Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?. <i>Sarcoma</i> , 2014 , 2014, 617102	3.1	11
197	Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. <i>Oncologist</i> , 2012 , 17, 1594-5	5.7	11

196	O-alkylcarboxylate oxime and N-hydroxyurea analogs of substituted indole leukotriene biosynthesis inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996 , 6, 1547-1552	2.9	11
195	A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). <i>Journal of Clinical Oncology</i> , 2006 , 24, 9514-9514 ²	2.2	11
194	Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10520-10520	2.2	11
193	SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS10578-TPS10578	2.2	11
192	A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. <i>Oncologist</i> , 2019 , 24, 857-863	5.7	11
191	Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9503-9503	2.2	10
190	A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10503-10503	2.2	10
189	Perspectives for immunotherapy in endocrine cancer. <i>Endocrine-Related Cancer</i> , 2016 , 23, R469-84	5.7	10
188	Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. <i>BMC Cancer</i> , 2019 , 19, 593	4.8	9
187	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. <i>Cancer</i> , 2019 , 125, 2445-2454	6.4	9
186	Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. <i>Targeted Oncology</i> , 2013 , 8, 295-300	5	9
185	Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery. <i>Cancer Investigation</i> , 2012 , 30, 300-8	2.1	9
184	Recent advances in therapy for gastrointestinal stromal tumors. <i>Current Oncology Reports</i> , 2007 , 9, 165-163	6.3	9
183	Immunity against soft-tissue sarcomas. <i>Current Oncology Reports</i> , 2003 , 5, 282-7	6.3	9
182	Divalent cations regulate glucagon binding. Evidence for actions on receptor-Ns complexes and on receptors uncoupled from Ns. <i>Biochemistry</i> , 1988 , 27, 1111-6	3.2	9
181	Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 10000-10000	2.2	9
180	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA10008-LBA10008	2.2	9
179	Novel fusion gene in aggressive angiomyxoma. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	8

178	Targeting sarcoma tumor-initiating cells through differentiation therapy. <i>Stem Cell Research</i> , 2017 , 21, 117-123	1.6	8
177	New strategies in sarcoma therapy: linking biology and novel agents. <i>Clinical Cancer Research</i> , 2012 , 18, 5837-44	12.9	8
176	A case of high-risk penile epithelioid hemangioendothelioma. <i>Nature Reviews Urology</i> , 2009 , 6, 223-7	5.5	8
175	Management dilemmas due to a paratracheal follicular dendritic cell tumor. <i>Annals of Thoracic Surgery</i> , 2006 , 82, 1898-900	2.7	8
174	Therapeutic impact of ET-743 (Yondelis; trabectedin), a new marine-derived compound, in sarcoma. <i>Current Opinion in Orthopaedics</i> , 2003 , 14, 419-428		8
173	Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9001-9001	2.2	8
172	Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10021-10021	2.2	8
171	Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4-4	2.2	8
170	Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11009-11009	2.2	8
169	A Method to Summarize Toxicity in Cancer Randomized Clinical Trials. <i>Clinical Cancer Research</i> , 2018 , 24, 4968-4975	12.9	8
168	Multiplexed Evaluation of Microdosed Antineoplastic Agents in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3958-3968	12.9	7
167	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. <i>Cancer</i> , 2019 , 125, 4435-4441	6.4	7
166	Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. <i>Frontiers in Oncology</i> , 2013 , 3, 9	5.3	7
165	Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. <i>Sarcoma</i> , 2009 , 2009, 575629	3.1	7
164	A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9515-9515	2.2	7
163	Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10508-10508	2.2	7
162	Efficacy of sorafenib in patients with desmoid-type fibromatosis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11065-11065	2.2	7
161	Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. <i>Journal of Clinical Oncology</i> , 2009 , 27, e13510-e13510	2.2	7

160	Management of Soft Tissue Sarcoma 2016 ,		7
159	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. <i>Future Oncology</i> , 2020 , 16, 4289-4301	3.6	6
158	Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2071-4	1.9	6
157	Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab. <i>BMJ Case Reports</i> , 2020 , 13,	0.9	6
156	The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST). <i>Clinical Sarcoma Research</i> , 2012 , 2, 21	2.5	5
155	Eribulin in soft-tissue sarcomas. <i>Lancet Oncology, The</i> , 2011 , 12, 988-9	21.7	5
154	Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab. <i>Journal of Clinical Oncology</i> , 2011 , 29, e638-40	2.2	5
153	Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series. <i>Annals of Oncology</i> , 2012 , 23, 804-805	10.3	5
152	Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 10079-10079	2.2	5
151	Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3039-3039	2.2	5
150	A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10003-10003	2.2	5
149	Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11037-11037	2.2	5
148	Gastrointestinal Stromal Tumor 2017 , 523-529		5
147	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. <i>Oncologist</i> , 2020 , 25, e1655-e1662	5.7	5
146	An unusual case of Kaposi sarcoma masquerading as cystitis in a kidney transplant recipient. <i>Transplant Infectious Disease</i> , 2019 , 21, e13132	2.7	4
145	Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. <i>Gastroenterology Clinics of North America</i> , 2016 , 45, 477-86	4.4	4
144	Psychological Distress of Internal Medicine Residents Rotating on a Hematology and Oncology Ward: An Exploratory Study of Patient Deaths, Personal Stress, and Attributed Meaning. <i>Medical Science Educator</i> , 2015 , 25, 413-420	0.7	4
143	Multidisciplinary management of soft-tissue sarcomas. <i>Cancer Investigation</i> , 2002 , 20, 818-24	2.1	4

142	Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST. 2013 ,		4
141	Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9013-9013	2.2	4
140	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9017-9017	2.2	4
139	Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9013-9013	2.2	4
138	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11061-11061	2.2	4
137	Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS11081-TPS11081	2.2	4
136	Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. <i>Clinical Sarcoma Research</i> , 2015 , 5, 21	2.5	3
135	Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 501-512	2.8	3
134	3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). <i>European Journal of Cancer</i> , 2015 , 51, S689	7.5	3
133	DNA copy number analysis in gastrointestinal stromal tumors using gene expression microarrays. <i>Cancer Informatics</i> , 2008 , 6, 59-75	2.4	3
132	Metastatic colon cancer to the ovaries in a Krukenberg-like pattern. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5255-6	2.2	3
131	Sarcoma. <i>Oncologist</i> , 2001 , 6, 333-7	5.7	3
130	An iterative synthesis of radiolabelled polyethylene glycol oligomers. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1989 , 27, 1437-1450	1.9	3
129	Activity of sorafenib against desmoid tumor/deep fibromatosis (DT/DF).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10013-10013	2.2	3
128	Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 10044-10044	2.2	3
127	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10514-10514	2.2	3
126	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA10502-LBA10502	2.2	3
125	Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumor (DT) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11032-11032	2.2	3

124	Sarcomas of Soft Tissue 2014 , 1753-1791.e10		3
123	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020 , 25, e1562-e1573	5.7	3
122	Sarcoma: The Merging of Science and Clinical Care. <i>Journal of Clinical Oncology</i> , 2018 , 36, 99-100	2.2	3
121	Contemporary Management of Metastatic Gastrointestinal Stromal Tumors: Systemic and Locoregional Approaches. <i>Oncology and Therapy</i> , 2016 , 4, 1-16	2.7	2
120	When Benign Tumors Mimic Malignancies: A Case of Lymphangiomatosis Masquerading as Metastatic Disease. <i>Rare Cancers and Therapy</i> , 2013 , 1, 21-27		2
119	Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. <i>Annals of Oncology</i> , 2012 , 23, ix478-ix479	10.3	2
118	Targeted therapy in sarcoma: should we be lumpers or splitters?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 652-7	7.1	2
117	Solitary Fibrous Tumor/Hemangiopericytoma 2013 , 179-184		2
116	9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 590	1.6	2
115	9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 590-591	1.6	2
114	Activity of gemcitabine plus docetaxel in leiomyosarcoma (LMS) and other histologies: Report of an expanded phase II trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9010-9010	2.2	2
113	Impact of ifosfamide-based chemotherapy on survival in patients with primary extremity synovial sarcoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9017-9017	2.2	2
112	Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the Phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST). <i>Journal of Clinical Oncology</i> , 2005 , 23, 9032-9032	2.2	2
111	A putative tumor suppressor role for Wnt-signaling in sarcomagenesis. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9507-9507	2.2	2
110	Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS). <i>Journal of Clinical Oncology</i> , 2007 , 25, 10061-10061	2.2	2
109	Outcomes of patients (pts) with advanced soft-tissue sarcomas (STS) treated in clinical trials (CTs) versus expanded access programs (EAPs): A decade of experience with single-agent trabectedin (Tr).. <i>Journal of Clinical Oncology</i> , 2010 , 28, 10029-10029	2.2	2
108	A model for multi-institutional, multidisciplinary sarcoma videoconferencing.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10521-10521	2.2	2
107	The somatic mutational landscape in soft tissue sarcoma: Early results from TCGA data.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10508-10508	2.2	2

106	Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10537-10537	2.2	2
105	In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3086-3086	2.2	2
104	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARCO24 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11505-11505	2.2	2
103	Fighting Cancer Through the Study of Sarcomas. <i>American Scientist</i> , 2005 , 93, 414	2.7	2
102	Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma (MFH) and Myxofibrosarcoma) 2016 , 143-152		2
101	Surgical Management of Sarcoma Metastatic to Liver. <i>Surgical Oncology Clinics of North America</i> , 2021 , 30, 57-67	2.7	2
100	Impact of Intraoperative Molecular Imaging after Fluorescent-Guided Pulmonary Metastasectomy for Sarcoma.. <i>Journal of the American College of Surgeons</i> , 2022 , 234, 748-758	4.4	2
99	Sarcoma. <i>Practical Guides in Radiation Oncology</i> , 2018 , 347-367	0	1
98	Sarcomas 2019 , 214-220		1
97	Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor 2013 , 149-160		1
96	Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). <i>Oncologist</i> , 2012 , 17, 1129-32	5.7	1
95	Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. <i>Cancer Investigation</i> , 2009 , 27, 402-6	2.1	1
94	Bluish papule in a middle-aged man. <i>Archives of Dermatology</i> , 2005 , 141, 1595-600		1
93	A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9523-9523	2.2	1
92	Pharmacodynamic case study of sunitinib/SU11248 in a gastrointestinal stromal tumor patient: Evidence toward a mechanism of effect. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9526-9526	2.2	1
91	Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10021-10021	2.2	1
90	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA10008-LBA10008	2.2	1
89	Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients following metastasectomy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS10103-TPS10103	2.2	1

88	Demonstration of gender-specific variability in a pharmacokinetic (PK) analysis of the PERSIST-5 trial of adjuvant imatinib (IM) for patients with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10538-10538	2.2	1
87	Stress and empathy among internal medicine trainees on an inpatient hematology-oncology ward.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 231-231	2.2	1
86	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 60-60	2.2	1
85	Gastrointestinal Stromal Tumors (GIST) and Their Management. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, S81-4		1
84	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS11590-TPS11590	2.2	1
83	Extraskeletal Osteogenic Sarcoma 2016 , 327-334		1
82	Gastrointestinal Stromal Tumors 2016 , 77-104		1
81	A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS10577-TPS10577	2.2	1
80	Uncommon/Unique Sites 2016 , 343-351		1
79	Alveolar Soft Part Sarcoma 2016 , 283-289		1
78	Clear Cell Sarcoma/Melanoma of Soft Parts 2013 , 267-273		1
77	Undifferentiated Pleomorphic Sarcoma (UPS; Malignant Fibrous Histiocytoma: MFH) and Myxofibrosarcoma 2013 , 129-136		1
76	General Statement as to Efficacy of Surgery/Chemotherapy/Radiation Therapy 2013 , 37-64		1
75	Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10551-10551	2.2	1
74	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2021 , JCO2003452	2.2	1
73	Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
72	Leiomyosarcoma 2013 , 113-127		1
71	GIST and Breast Cancer: 3 Case Reports and a Review of the Literature. <i>Current Cancer Therapy Reviews</i> , 2009 , 5, 100-104	0.4	0

70	Utility of immune checkpoint inhibitors (ICI) in 3 patients (pts) with sarcomas of antigen presenting cells (follicular dendritic cell sarcoma [FDSC], histiocytic sarcoma [HS]).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e23574-e23574	2.2	○
69	Epithelioid Sarcoma 2016 , 237-241		○
68	MEDICAL ONCOLOGY OF SOFT TISSUE SARCOMAS1070-1082		○
67	Leiomyosarcoma 2016 , 125-142		○
66	General Description 2016 , 3-17		○
65	Introduction to Soft Tissue Sarcoma 2017 , 489-497		○
64	Sarcomas More Common in Children 2013 , 221-250		○
63	Natural History: Importance of Size, Site, and Histopathology 2013 , 19-35		○
62	A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS11583-TPS11583	2.2	○
61	SELNET clinical practice guidelines for bone sarcoma.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 174, 103685	7	○
60	General Description 2013 , 1-17		
59	Synovial Sarcoma 2013 , 137-147		
58	The mechanistic target of rapamycin pathway in sarcomas: from biology to therapy. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 653-664	1.1	
57	Introduction: the 2008 European society for medical oncology international symposium on sarcomas and gastrointestinal stromal tumors. <i>Seminars in Oncology</i> , 2009 , 36, 289	5.5	
56	CYP3A4/5 and pharmacogenetics in patients with sarcoma - AuthorsReply. <i>Lancet Oncology</i> , 2007 , 8, 668-9	21.7	
55	Sarcomas of Soft Tissue 2002 , 197-203		
54	Molecular profiling of liposarcoma subtypes. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9016-9016	2.2	
53	A comparison of three clinical factors as predictive markers for response to immunotherapy in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e21158-e21158	2.2	

- 52 Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. *Journal of Clinical Oncology*, **2018**, 36, e23570-e23570 2.2
- 51 Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).. *Journal of Clinical Oncology*, **2018**, 36, 11513-11513 2.2
- 50 Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT).. *Journal of Clinical Oncology*, **2015**, 33, 10561-10561 2.2
- 49 Sarcomas More Common in Children **2016**, 243-274
- 48 Malignant Peripheral Nerve Sheath Tumor (MPNST) and Triton Tumor **2016**, 165-176
- 47 Radiation-Induced Sarcoma **2016**, 275-281
- 46 Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis) **2016**, 177-194
- 45 Solitary Fibrous Tumor/Hemangiopericytoma **2016**, 195-201
- 44 Extraskeletal Myxoid Chondrosarcoma **2016**, 307-313
- 43 Liposarcoma **2016**, 105-124
- 42 Other Uterine Sarcomas **2016**, 315-326
- 41 Reactive Lesions **2016**, 387-390
- 40 Natural History: Importance of Size, Site, Histopathology **2016**, 19-40
- 39 Desmoplastic Small Round Cell Tumor **2016**, 299-305
- 38 General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy **2016**, 41-74
- 37 Sustentacular Tumors of Lymph Tissue **2016**, 335-341
- 36 Synovial Sarcoma **2016**, 153-163
- 35 Clear Cell Sarcoma/Melanoma of Soft Parts **2016**, 291-297

34 Vascular Sarcomas **2016**, 221-236

33 Visualizing toxicity: A single score to summarize toxicity in randomized clinical trials.. *Journal of Clinical Oncology*, **2016**, 34, 6605-6605 2.2

32 Sarcoma tumor size (T) staging: Are radiology or pathology measurements more appropriate?. *Journal of Clinical Oncology*, **2017**, 35, e22522-e22522 2.2

31 Safety and efficacy of trabectedin when administered in the inpatient vs. outpatient setting in a subset analysis of a phase III randomized clinical trial.. *Journal of Clinical Oncology*, **2017**, 35, e22516-e22516 2.2

30 Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST). *Blood*, **2010**, 116, 2276-2276 2.2

29 Genome-wide analysis and characterization of an online sarcoma cohort.. *Journal of Clinical Oncology*, **2012**, 30, 10097-10097 2.2

28 Tenosynovial giant cell tumor (TGCT)/pigmented villonodular synovitis (PVNS): Outcome of 313 patients before the era of kinase inhibitors.. *Journal of Clinical Oncology*, **2012**, 30, 10022-10022 2.2

27 How well do we communicate risk? An evaluation of AJCC version 6 and 7 staging systems for soft tissue sarcomas.. *Journal of Clinical Oncology*, **2012**, 30, 10001-10001 2.2

26 Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy.. *Journal of Clinical Oncology*, **2012**, 30, 10013-10013 2.2

25 Advanced soft-tissue sarcoma in patients over age 75: Patterns of care and survival.. *Journal of Clinical Oncology*, **2012**, 30, 10057-10057 2.2

24 Desmoplastic Small Round Cell Tumor **2013**, 275-280

23 Alveolar Soft Part Sarcoma **2013**, 259-265

22 Reactive Lesions **2013**, 355-358

21 Desmoid Tumor/Deep-Seated Fibromatosis (Desmoid-Type Fibromatosis) **2013**, 161-177

20 Gastrointestinal Stromal Tumors (GISTs) **2013**, 67-91

19 Epithelioid Sarcoma **2013**, 215-219

18 Fibrosarcoma and Its Variants **2013**, 185-200

17 Benign Soft Tissue Tumors **2013**, 339-354

- 16 Other Uterine Sarcomas **2013**, 289-299
- 15 Extraskelatal Myxoid Chondrosarcoma **2013**, 281-287
- 14 Vascular Sarcomas **2013**, 201-213
- 13 Uncommon/Unique Sites **2013**, 317-326
- 12 Mostly Benign/Rarely Metastasizing Soft Tissue Tumor **2013**, 329-337
- 11 Extraskelatal Osteogenic Sarcoma **2013**, 301-307
- 10 Radiation-Induced Sarcomas **2013**, 251-257
- 9 Sustentacular Tumors of Lymph Tissue **2013**, 309-315
- 8 Liposarcoma **2013**, 93-111
- 7 Uterine Sarcomas in the Elderly **2013**, 319-348
- 6 Linking kinases to adverse events through kinase inhibitors.. *Journal of Clinical Oncology*, **2013**, 31, e13524-e13524
- 5 Adult Pleomorphic Rhabdomyosarcomas: Assessing Outcomes Associated with Radiotherapy and Chemotherapy Use in the National Cancer Database. *Sarcoma*, **2021**, 2021, 9712070 3.1
- 4 Fibrosarcoma and Its Variants **2016**, 203-219
- 3 Mostly Benign/Rarely Metastasizing **2016**, 355-367
- 2 Selected Benign Tumors **2016**, 369-386
- 1 Comments regarding lung metastasis surgery for sarcoma. *Oncology*, **2011**, 25, 1210-1 1.8